Chitinase-3-Like-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Chitinase-3-Like-2 (CHI3L2/YKL-39, UniProt Q15782), expressed in HEK293 cells. Suitable for glycan-binding assays, antibody validation, and inhibitor screening studies.
Expression system
HEK293
Cat. #
REC-Chitinase3Like2

In stock

SKU
REC-Chitinase3Like2
$498.00

Target Overview

Chitinase-3-Like-2 (CHI3L2), also catalogued as Chondrocyte Protein 39 (CP-39) and YKL-39, is a 390-amino-acid secreted lectin encoded by the CHI3L2 gene (UniProt Q15782). Despite sharing structural homology with glycoside hydrolase family 18 chitinases, CHI3L2 lacks chitinase enzymatic activity; the protein binds chitooligosaccharides and other glycans with high affinity but does not hydrolyse chitin. It does not bind heparin, a property that distinguishes it from several related family members. This recombinant is expressed in HEK293 mammalian cells, providing post-translational modifications — including N-linked glycosylation — consistent with the native secreted form. Mammalian expression is particularly relevant given recent published findings that glycosylation state influences the biological interactions of chitinase-like proteins (Wang Y et al., Nat Commun, 2026; PMID 41951645). The full-length mature sequence (390 residues) is produced without a signal peptide, as is standard for secreted recombinant formats. Researchers use this recombinant for several bench applications: direct glycan- and chitooligosaccharide-binding assays to characterise lectin affinity and selectivity, competitive displacement experiments to profile candidate inhibitors, and surface plasmon resonance or biolayer interferometry studies to obtain binding kinetics. In antibody validation workflows, recombinant CHI3L2 serves as a well-characterised positive-control antigen for Western blot and ELISA; researchers using this protein for such validation can pair it with the matched Triple Point Biologics antibody (SKU: RP-Chitinase3Like2), which has been validated for Western blot against human targets. The recombinant is also used as a coating antigen in immunoassay development and as a reference standard in expression-profiling studies across tissue types and disease models.

Background

CHI3L2 belongs to the chitinase-like protein (CLP) family — a group of glycan-binding lectins that have lost catalytic activity but retain the ability to engage chitin-derived oligosaccharides and extracellular matrix components. The protein is constitutively expressed in chondrocytes (where it was first isolated as the 39 kDa Chondrocyte Protein), and subsequently detected in a range of other tissues and cell types under both homeostatic and disease-associated conditions. In the context of inflammatory joint disease, CHI3L2 has attracted attention as a potential tissue-compartment marker. A 2026 single-cell analysis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial tissue identified differential fibroblast populations with distinct phenotypic and functional characteristics (Tynan Ó et al., Ann Rheum Dis, 2026; PMID 41966860), situating chitinase-like proteins within the broader landscape of stromal biology in autoimmune arthritis — a context in which CHI3L2 recombinant protein is used to map protein-level expression and to validate antibody reagents targeting synovial fibroblast markers. CHI3L2 has also been studied as a research target in oncology. Published work demonstrates that CHI3L2 expression is elevated in glioblastoma and that targeting it suppresses cell proliferation and migration in vitro (Liu Z et al., Transl Cancer Res, 2026; PMID 41969515). Recombinant CHI3L2 supports this line of inquiry by providing a defined antigen for screening neutralising or blocking agents, and for establishing dose-response relationships in cell-based functional assays. Within the macrophage biology field, chitinase-like proteins have been shown to de-N-glycosylate the scavenger receptor CD36, thereby modifying cholesterol metabolism in atherosclerotic macrophages (Wang Y et al., Nat Commun, 2026; PMID 41951645). Although this work primarily implicates CHI3L1, the structural relatedness of CHI3L2 makes recombinant CHI3L2 a useful comparator reagent for dissecting isoform-specific contributions to glycan remodelling and lipid metabolism. In neurological disease research, chitinase family members — including CHI3L2 — show constitutive neuronal expression and disease-associated upregulation in amyotrophic lateral sclerosis (ALS) tissue (Gaur N et al., Brain, 2026; PMID 41762671), establishing recombinant CHI3L2 as a relevant reference standard for quantitative immunoassays and proteomic studies in neurodegenerative disease models. Across these research areas, the HEK293-expressed recombinant provides a glycosylated, secreted-format protein suitable for binding studies, inhibitor profiling, and immunological validation — applications requiring a well-defined, mammalian-derived reference antigen.

Applications

  • Chitooligosaccharide and glycan binding assays to determine lectin affinity and selectivity (e.g., direct ELISA or microarray format)
  • Inhibitor screening and IC50 determination using competitive displacement of fluorescently labelled chitooligosaccharide ligands
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) to obtain binding kinetics for glycan or antibody interactions
  • Western blot positive-control antigen for validation of anti-CHI3L2 antibodies, including the matched Triple Point Biologics antibody (RP-Chitinase3Like2)
  • ELISA coating antigen for immunoassay development and quantification of anti-CHI3L2 antibody titres
  • Antibody-blocking and neutralisation assays in cell-based models of glioblastoma proliferation or migration
  • Isoform-specificity comparator reagent alongside recombinant CHI3L1 in glycan-remodelling or macrophage cholesterol metabolism studies
  • Reference standard for quantitative mass spectrometry or immunoassay-based expression profiling in synovial tissue, CNS, or tumour specimens

References

  1. Liu Z et al. Targeting chitinase-3-like protein 2 (CHI3L2) suppresses cell proliferation and migration in glioblastoma. Transl Cancer Res. 2026. doi:10.21037/tcr-2025-aw-2353. PMID: 41969515.
  2. Tynan Ó et al. RA and PsA synovial tissue single-cell analysis demonstrates differential fibroblast populations with distinct phenotypes and functional capacities. Ann Rheum Dis. 2026. doi:10.1016/j.ard.2026.03.010. PMID: 41966860.
  3. Wang Y et al. Chitinase-like proteins de-N-glycosylating CD36 modify cholesterol metabolism in atherosclerotic macrophages. Nat Commun. 2026. doi:10.1038/s41467-026-71388-x. PMID: 41951645.
  4. Kumar S et al. Integrative Multi-Omics and Single-Cell Profiling Identify Chitinase Domain Containing Protein 1 (CHID1) as a Prognostic Biomarker in Glioblastoma. J Cancer. 2026. doi:10.7150/jca.130519. PMID: 41869455.
  5. Gaur N et al. Constitutive neuronal expression and disease-associated upregulation of chitinases in amyotrophic lateral sclerosis. Brain. 2026. doi:10.1093/brain/awag083. PMID: 41762671.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; macrophage/neutrophil granules

Frequently Asked Questions

What is the expected molecular weight of recombinant CHI3L2 on SDS-PAGE and Western blot?

The mature CHI3L2 sequence spans 390 residues, giving a predicted polypeptide MW of approximately 43 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation is present and consistent with the native secreted form; the apparent MW on reducing SDS-PAGE typically runs at 45–50 kDa, slightly above the theoretical mass. On Western blot you may observe a diffuse or doublet band in this range reflecting glycoform heterogeneity — this is expected and not a purity concern. Purity is confirmed at >95% by SDS-PAGE.

Does recombinant CHI3L2 YKL-39 have chitinase enzymatic activity or does it cleave chitin substrates?

CHI3L2 (YKL-39/CP-39) lacks chitinase enzymatic activity despite its structural homology to glycoside hydrolase family 18 members. A critical substitution at the catalytic glutamate abolishes hydrolytic function. This recombinant will bind chitooligosaccharides and related glycan ligands with high affinity, but it will not hydrolyze chitin or fluorogenic chitin-based substrates such as 4-MU-GlcNAc2. Assay designs should therefore focus on ligand-binding, competitive displacement, or receptor-interaction readouts rather than enzymatic cleavage assays.

What assay format and substrate should I use to measure CHI3L2 glycan-binding activity in vitro?

Because CHI3L2 is a catalytically inactive chitin-binding lectin, standard chromogenic or fluorogenic hydrolysis assays are not applicable. Validated approaches include surface plasmon resonance or biolayer interferometry with immobilized chitooligosaccharides (e.g., (GlcNAc)4–(GlcNAc)6), competitive ELISA-based displacement assays, or pull-down experiments with chitin-conjugated beads. For cell-based receptor-binding studies, a starting concentration of 0.5–5 µg/mL in serum-free medium is a reasonable titration range; optimize empirically for your cell type and readout.

What buffer is recombinant Chitinase-3-Like-2 supplied in and how should I dilute it for binding assays?

This recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For most binding or cell-based assays, a 1:10 to 1:20 dilution into your assay buffer (e.g., PBS + 0.1% BSA, or serum-free DMEM) is a practical starting point, keeping glycerol below 0.5% final to avoid cytotoxicity or assay interference. Note that CHI3L2 does not bind heparin, so heparin-containing blocking buffers will not sequester the protein — a meaningful difference from several related family members.

How should I store recombinant CHI3L2 to maintain activity and what is the shelf life?

Store at −20°C in the single-use aliquots provided. Avoid repeated freeze-thaw cycles, which can promote aggregation and reduce glycan-binding activity. Working aliquots kept at 4°C are stable for up to 48–72 hours; for longer bench-side use, adding carrier protein (0.1% BSA) is advisable if your downstream assay permits it. Under recommended storage conditions, activity is guaranteed for 12 months from the date of receipt. Do not store in frost-free freezers subject to temperature cycling.

Can I use recombinant CHI3L2 as a positive control for Western blot with the matched TPB anti-CHI3L2 antibody RP-Chitinase3Like2?

Yes — this is one of the primary use cases for pairing REC-Chitinase3Like2 with RP-Chitinase3Like2. The rabbit polyclonal antibody was raised and validated against the same recombinant, guaranteeing immunoreactivity on Western blot. Load 20–50 ng of recombinant per lane on a standard 10–12% SDS-PAGE gel; expect a band at 45–50 kDa under reducing conditions. This also serves as a reliable positive control for antibody lot-to-lot consistency checks and for validating new detection secondaries against a defined antigen quantity.

How much recombinant CHI3L2 should I load for Western blot to establish a positive control band?

For a clean, well-resolved positive control band using RP-Chitinase3Like2, load 20–50 ng of REC-Chitinase3Like2 per lane alongside your lysate samples. At 20 ng you should see a strong signal with the polyclonal at a 1:1,000–1:2,000 primary antibody dilution; at 50 ng the band is robust enough to serve as a semi-quantitative reference even on lower-sensitivity detection systems. Because the recombinant carries native-like N-glycosylation from HEK293 expression, the band position accurately reflects what you expect from secreted endogenous CHI3L2 in conditioned medium or synovial fluid samples.

What is the isoform and processing state of this recombinant CHI3L2 — does it include the signal peptide?

This recombinant corresponds to the full-length mature form of human CHI3L2 (UniProt Q15782), encompassing all 390 residues of the processed protein. The N-terminal signal peptide (residues 1–21 by canonical annotation) is excluded, as is standard practice for secreted proteins expressed in HEK293 — the signal sequence is not present in the secreted native protein and would be cleaved co-translationally anyway. No additional pro-domains or affinity tags are present in the final product. The sequence is consistent with the predominant circulating and synovial fluid form documented in the literature.

Validation imagery coming soon

Western blot validation figures for REC-Chitinase3Like2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →